Clinical Trial Update: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating trilaciclib in combination with sacituzumab govitecan-hziy for triple-negative breast cancer was terminated; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab govitecan-hziy (sacituzumab govitecan-hziy)
• trilaciclib (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-01-29